8-K: Seres Therapeutics Announces Positive Biomarker Data for SER-155 and Provides Corporate Update

Seres Therapeutics reported positive biomarker data from its SER-155 Phase 1b study, showing improved epithelial barrier integrity and reduced systemic inflammation, and announced a cash runway extended into Q1 2026.

Summary

• Seres Therapeutics announced new translational biomarker results from its SER-155 Phase 1b clinical study, showing a statistically significant decrease in fecal albumin and a positive impact on biomarkers of systemic inflammation and immune homeostasis compared to placebo.
• These results are consistent with SER-155's mechanism of action and support its potential to reduce bloodstream infections by improving epithelial barrier integrity.
• The company also reported that it had approximately $31 million in cash and cash equivalents as of December 31, 2024.
• Based on existing cash and projected payments from Nestl Health Science, Seres expects to fund operations into the first quarter of 2026.
• The FDA granted Breakthrough Therapy designation to SER-155 in December 2024 for the reduction of bloodstream infections in adults undergoing allo-HSCT.
• Seres has submitted a Briefing Book to the FDA and expects feedback in the first quarter of 2025 regarding a potential next registrational study of SER-155.

Sentiment

Score: 8

Explanation: The document presents positive clinical data, a strong cash position, and a clear path forward with regulatory engagement. The company is actively seeking partnerships, which is a positive sign for future growth. However, the need for additional capital and the preliminary nature of the financial results temper the overall sentiment slightly.

Positives

• The biomarker data provides further evidence of SER-155's potential to reduce bloodstream infections.
• The company has a cash runway into the first quarter of 2026, providing financial stability for ongoing operations.
• The Breakthrough Therapy designation from the FDA could expedite the development and approval process for SER-155.
• Market research suggests a strong value proposition for SER-155 due to the high unmet need for preventing bloodstream infections in allo-HSCT patients.
• SER-155 clinical results have been accepted for an oral presentation at the 2025 TANDEM Meeting.

Negatives

• The cash and cash equivalents figure of $31 million is preliminary and unaudited, subject to change upon completion of financial closing procedures.
• The company is still seeking a partner to provide financial resources and other capabilities to maximize the SER-155 opportunity.

Risks

• The preliminary financial results are subject to change based on the completion of closing and review procedures.
• The company's ability to secure a partnership and/or generate additional capital is uncertain.
• There are risks associated with the company's novel approach to therapeutic intervention and reliance on third parties for clinical trials and manufacturing.
• The company faces competition in the market for live biotherapeutics.
• The company may not be able to realize the anticipated benefits of the VOWST sale.

Future Outlook

The company expects to fund operations into the first quarter of 2026 based on existing cash and projected payments from Nestl Health Science, and plans to engage with the FDA regarding a potential registrational study for SER-155. They are also actively seeking a partner to maximize the SER-155 opportunity.

Management Comments

• Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, stated that the company is making progress in advancing clinical development of SER-155 in allo-HSCT.
• Mr. Shaff also mentioned that the company believes the medical and commercial opportunity for SER-155 is substantial.
• Mr. Shaff noted that the new SER-155 biomarker data expands upon previously reported clinical results and strengthens the mechanistic understanding of the potential of SER-155.
• Wendy Garrett, M.D. Ph.D., commented that the SER-155 translational biomarker data, combined with the promising clinical results, provide strong biological evidence supporting Seres live biotherapeutic candidates.

Industry Context

This announcement is significant in the live biotherapeutics space, as it provides further evidence of the potential of microbiome-based therapies to address serious medical conditions. The positive biomarker data for SER-155, combined with the Breakthrough Therapy designation, positions Seres as a key player in this emerging field. The company's focus on preventing bloodstream infections in vulnerable patient populations aligns with a growing need for effective prophylactic treatments.

Comparison to Industry Standards

• The 77% relative risk reduction in bloodstream infections observed with SER-155 is a strong result compared to standard prophylactic treatments, which often have limited efficacy and can lead to antibiotic resistance.
• Other companies in the microbiome therapeutics space, such as Finch Therapeutics and Vedanta Biosciences, are also developing treatments for various conditions, but SER-155's focus on bloodstream infections in allo-HSCT patients is a unique and potentially high-value niche.
• The Breakthrough Therapy designation from the FDA is a significant advantage for Seres, as it can expedite the development and approval process compared to companies without this designation.
• The cash runway into Q1 2026 provides a reasonable timeframe for Seres to advance its clinical programs and secure partnerships, which is comparable to other companies in the biotech sector at a similar stage of development.

Stakeholder Impact

• Shareholders will likely view the positive biomarker data and extended cash runway favorably.
• Employees may feel more secure about the company's financial stability and future prospects.
• Patients undergoing allo-HSCT may benefit from the potential of SER-155 to reduce bloodstream infections.
• Payers may see the value proposition of SER-155 as a cost-effective prophylactic treatment.

Next Steps

• The company expects feedback from the FDA in the first quarter of 2025 regarding a potential next registrational study of SER-155.
• Seres will present SER-155 clinical results at the TANDEM Meeting in February 2025.
• The company will continue to evaluate cash preservation actions and timing of investments.
• Seres intends to seek partnerships to further evaluate the opportunities for its biotherapeutic candidates.

Key Dates

Keywords

SER-155, live biotherapeutics, bloodstream infections, allo-HSCT, biomarkers, epithelial barrier integrity, inflammation, FDA, Breakthrough Therapy, cash runway